IP Library Granted Patent US 10,752,662
Granted Patent B2
US 10,752,662 · App. 15/883,999 · Granted Aug 25, 2020

Anti-inflammatory compounds and methods of use

Inventors: Karen Guillemin (Eugene, OR); Annah Rolig (Eugene, OR); Emily Sweeney (Eugene, OR)
Assignee: University of Oregon
C07K14/4702A61P29/00C07K4/12C12N15/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,752,662
App. No.
15/883,999
Granted
Aug 25, 2020
Kind
B2
Abstract

Methods of treating or inhibiting inflammation in a subject include administering an anti-inflammatory protein to the subject. In some embodiments, the protein has at least 80% sequence identity to the amino acid sequence set forth as SEQ ID NO: 1, SEQ ID NO: 17, or fragments thereof. Isolated polypeptides, nucleic acids, and recombinant vectors including a nucleic acid encoding the anti-inflammatory protein (such as a nucleic acid encoding a protein with at least 80% sequence identity to SEQ ID NO: 1, SEQ ID NO: 17, or fragments thereof) operably linked to a heterologous promoter are also disclosed.

Claims (6)

1. A method of treating inflammatory bowel disease, Hirschsprung's associated enterocolitis, irritable bowel syndrome, or necrotizing enterocolitis in a subject, comprising administering to the subject a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence 130-190 amino acids in length comprising amino acids 1-185 of SEQ ID NO: 1, amino acids 23-185 of SEQ ID NO: 1, or amino acids 192-313 of SEQ ID NO: 1.

2. The method of claim 1 , wherein the amount of the polypeptide administered to the subject is about 1 mg to about 5 g.

3. The method of claim 1 , wherein the polypeptide is administered to the subject daily, weekly, or monthly.

4. The method of claim 1 , further comprising administering one or more additional anti-inflammatory therapies to the subject.

5. The method of claim 1 , wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 1, amino acids 1-185 of SEQ ID NO: 1, amino acids 23-185 of SEQ ID NO: 1, or amino acids 192-313 of SEQ ID NO: 1.

6. The method of claim 1 , wherein the inflammatory bowel disease is ulcerative colitis or Crohn's disease.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2018
From: GUILLEMIN, KAREN; ROLIG, ANNAH; SWEENEY, EMILY
To: UNIVERSITY OF OREGON
Reel/Frame 044900/0016 →
CONFIRMATORY LICENSE Recorded Feb 6, 2018
From: UNIVERSITY OF OREGON
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 045261/0008 →
Continuity (3)
Continuation In Part 15311667
Provisional Application 61994601 · May 16, 2014
Related Publication 20180194820A1 · Jul 12, 2018